PRESS RELEASE published on 09/14/2023 at 14:30, 2 years 10 months ago Jaguar Health Shares Presentation Replay Link from September 11-13, 2023 H.C. Wainwright Annual Global Investment Conference
PRESS RELEASE published on 09/13/2023 at 14:30, 2 years 10 months ago Patent Issued in Japan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
PRESS RELEASE published on 09/12/2023 at 14:30, 2 years 11 months ago Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to National Institute of Allergy and Infectious Diseases for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea
PRESS RELEASE published on 09/11/2023 at 14:30, 2 years 11 months ago Jaguar Health Shares Replay Link for September 7, 2023 Presentation at Emerging Growth Conference
PRESS RELEASE published on 09/07/2023 at 14:30, 2 years 11 months ago Jaguar Health's Executive VP Dr. Karen Brunke Joins BIO's Rare Disease and Orphan Drugs Committee
PRESS RELEASE published on 08/30/2023 at 14:30, 2 years 11 months ago The Science Times Publishes Article About Jaguar Health's Focus on Developing Crofelemer for Two Rare Disease Indications
PRESS RELEASE published on 08/28/2023 at 14:30, 2 years 11 months ago Jaguar Health to Present September 7 at Emerging Growth Conference and at the September 11-13 H.C. Wainwright Annual Global Investment Conference
PRESS RELEASE published on 08/24/2023 at 13:00, 2 years 11 months ago Jaguar Health Engages B2i Digital to Deploy Cutting-Edge Investor Engagement Campaign
PRESS RELEASE published on 08/17/2023 at 14:30, 2 years 11 months ago Napo Pharmaceuticals, a Jaguar Health Family Company, Reports Completion of Last Patient Last Visit for its Pivotal Phase 3 OnTarget Trial of Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea
PRESS RELEASE published on 08/16/2023 at 14:30, 2 years 11 months ago Napo Pharmaceuticals Surveys of Neurologists, Patients, and Caregivers Regarding Amyotrophic Lateral Sclerosis (ALS) Treatment Indicate Real World Burden of Diarrhea and Potential Treatment Interruption
Published on 08/12/2026 at 23:30, 1 hour 34 minutes ago CCL Industries Announces Record Results for 2026 Second Quarter
Published on 08/12/2026 at 23:30, 1 hour 34 minutes ago Bolt Metals to Rebrand as 26 Metals Inc. and Adopt the Ticker "IRON," Highlighting Its Focus on Flagship Florália Iron Project in Brazil's Iron Quadrangle
Published on 08/12/2026 at 23:20, 1 hour 44 minutes ago RJK Explorations Ltd. Announces Upsize of Previously Announced Private Placement
Published on 08/12/2026 at 23:05, 1 hour 59 minutes ago Vox Royalty Reports Q2 2026 Results And Declares Quarterly Dividend
Published on 08/12/2026 at 21:05, 3 hours 58 minutes ago Aurisco Pharmaceutical is the First Generic Oligonucleotide Manufacturer in the World successfully inspected by USFDA
Published on 08/12/2026 at 19:57, 5 hours 6 minutes ago EQS-Adhoc: Hypoport SE: Hypoport SE resolves share buyback programme with a volume of up to EUR 10 million
Published on 08/12/2026 at 19:37, 5 hours 26 minutes ago EQS-Adhoc: Brockhaus Technologies AG: Preliminary revenue for H1 2026 at €13.4 million and adjusted EBITDA at €-0.5 million; forecast for the continuing operations unchanged
Published on 08/11/2026 at 17:45, 1 day 7 hours ago DAMARTEX / Droits de vote bruts et réels au 31 juillet 2026
Published on 08/11/2026 at 17:40, 1 day 7 hours ago Infotel : Déclaration des transactions sur actions propres réalisées du 3 au 7 août 2026 dans le cadre du programme de rachat d’actions
Published on 08/10/2026 at 18:00, 2 days 7 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 2 days 7 hours ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
